Safety in melatonin use;Seguridad en el uso de la melatonina

Actas Espanolas de Psiquiatria

Volumn 29, Issue 5, 2001, Pages 334-337

  Morera, A L ^a   Henry, M ^a   De La Varga, M ^b  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b Hospital de Tenerife   (Spain)

Author keywords

Adverse effects; Melatonin; Side effects; Toxicity

Indexed keywords

MELATONIN;

HUMAN; REVIEW;

HUMANS; MELATONIN;

EID: 0035459290     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lerner AB, Case JD, Takahashi Y, Lee T, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958;80:2587.
2. Becker WH. Epiglandol bei dementia praecox. Ther Halbmonatshefte 1920;34:667-8.
3. Altschule MD, Siegel EP, Goncz RM, Murnane JR. Effect of pineal extracts on blood glutathione level in psychotic patients. Arch Neurol Psychiatr 1954;71: 615-8.
4. Eldred SH, Bell NW, Sherman LJ. A pilot study comparing the effects of pineal extract and a placebo in patients with chronic schizophrenia. N Engl J Med 1960;263:1330-5.
5. Carman JS, Post RM, Buswell R, Goodwin FK. Negative effects of melatonin on depression. Am J Psychiatry 1976;133:1181-6.
6. Mendlewicz J, Linkowski P, Branchey L, Weinberg U, Weitzman ED, Branchey M. Abnormal 24 hour pattern of melatonin secretion in depression. Lancet 1979;2:1362.
7. Conde V, Cuesta MI, Sigüenza A. Contribución preliminar al estudio diferencial de la secreción nocturna de melatonina en pacientes psiquiátricos, depresivos y controles sanos. Actas Luso-Esp Neurol Psiquiatr Cienc Afines 1987;15:9-19.
8. Claustrat B, Brun J, David M, Sassolas G, Chazot G. Melatonin and jet lag: confirmatory result using a simplified protocol. Biol Psychiatry 1992;32:705-11.
9. Sahelian R. Use of melatonin for insomnia. Am Fam Physician 1998;57:1783.
10. Melatonin. Medical Letter 1995;37:111-2.
11. Kendler BS. Melatonin: media hype or therapeutic breakthrough? Nurse Pract 1997;22:66-2.
12. Pestaña A. El MedLine como fuente de información bibliométrica de la producción española en biomedicina y ciencias medicas. Comparación con el Science Citation Index. Med Clin (Barc) 1997;109:506-11.
13. Middleton BA, Stone BM, Arendt J. Melatonin and fragmented sleep patterns. Lancet 1996;348:551-2.
14. Porter LM. Can melatonin cause severe headaches? RN 1996;59:75.
15. BalentineJ, Hagman J. More on melatonin. J Am Acad Child Adolesc Psychiatry 1997;36:1013.
16. Force RW, Hansen L, Bedell M. Psychotic episode after melatonin. Ann Pharmacother 1997;31:1408.
17. Holliman BJ, Chyka PA. Problems in assessment of acute melatonin overdose. South Med J 1997;90: 451-3.
18. Hong YG, Riegler JL. Is melatonin associated with the development of autoimmune hepatitis? J Clin Gastroenterol 1997;25:376-8.
19. Bardazzi F, Placucci F, Neri I, D'Antuono A, Patrizi A. Fixed drug eruption due to melatonin. Acta Derm Venereol 1998;78:69-70.
20. Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998;351: 1254.
21. Lehman NL, Johnson LN. Toxic optic neuropathy after concomitant use of melatonin, zoloft, and a high-protein diet. J Neuroophthalmol 1999;19:232-4.
22. Tornado de: http://promini.medscape.com/drugdb/ fdbcredits.htlm
23. Tornado de: http://promini.medscape.com/drugdb/ drug_adverse_effects.asp
24. Lerner AB, Nordlund JJ. Melatonin: clinical pharmacology. J Neural Transm 1978;(Supl 13):339-47.
25. Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ. Effects of melatonin on human mood and performance. Brain Res 1984;323:201-7.
26. Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 1999; 74:443-7.
27. Melatonin. Drugs RD 1999;1:483-5.
28. Vriend J. Evidence for pineal gland modulation of the neuroendocrine-thyroid axis. Neuroendocrinology 1983;36:68-78.
29. Sánchez-Forte M, Moreno M, Muñoz H, Molina C, Acuña C, Molina F. Efecto de la melatonina como anticonvulsivante y protector neuronal. Rev Neurol 1997;25:1229-34.
30. Laforce R, Rigozzi K, Paganetti M, Mossi W, Guainazzi P. Aspects of melatonin manufacturing and requirements for a reliable active component. Biol Signals Recept 1999;8:143-6.
31. Arendt J. Safety of melatonin in long-term use (?). J Biol Rhythms 1997;12:673-81.